Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Challenges associated with hereditary cancer susceptibility testing.

Mayer DK.

Clin J Oncol Nurs. 2014 Feb;18(1):14-5. doi: 10.1188/14.CJON.14-15.

2.
3.
4.

The prevention of hereditary breast cancer.

Rodriquez E, Domchek SM.

Semin Oncol. 2007 Oct;34(5):401-5. Review.

PMID:
17920894
5.

BRCA1 and BRCA2: 1994 and beyond.

Narod SA, Foulkes WD.

Nat Rev Cancer. 2004 Sep;4(9):665-76. Review.

PMID:
15343273
6.

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.

Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL.

Breast Cancer Res. 2011 Feb 28;13(1):R20. doi: 10.1186/bcr2832.

7.

Risk assessment for hereditary breast cancer: BRCA1 and BRCA2.

Seenandan-Sookdeo KA, Sawatzky JA.

Can Oncol Nurs J. 2010 Summer;20(3):107-15. English, French.

PMID:
20812602
8.

[Function of BRCA1 and BRCA2 genes associated with hereditary predisposition to breast cancer].

Jasińska A, Krzyzosiak WJ.

Postepy Biochem. 2001;47(2):146-59. Review. Polish. No abstract available.

PMID:
11757317
9.

Current perspectives on BRCA1- and BRCA2-associated breast cancers.

Phillips KA.

Intern Med J. 2001 Aug;31(6):349-56. Review.

PMID:
11529589
10.

Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress.

van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, Bröcker-Vriends AH, van Asperen CJ, Sijmons RH, Seynaeve C, Van Gool AR, Klijn JG, Tibben A.

Patient Educ Couns. 2007 Jan;65(1):58-68. Epub 2006 Jul 26.

PMID:
16872788
11.

Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.

Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M, Kant R, Gupta V, Shukla NK, Deo SS, Das BC.

Breast Cancer Res Treat. 2004 Nov;88(2):177-86.

PMID:
15564800
12.

BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management.

Marchina E, Fontana MG, Speziani M, Salvi A, Ricca G, Di Lorenzo D, Gervasi M, Caimi L, Barlati S.

Oncol Rep. 2010 Dec;24(6):1661-7.

PMID:
21042765
13.
14.

Identifying and managing hereditary risk of breast and ovarian cancer.

Frank TS, Critchfield GC.

Clin Perinatol. 2001 Jun;28(2):395-406. Review.

PMID:
11499060
15.

Collaboration of breast cancer clinic and genetic counseling division for BRCA1 and BRCA2 mutation family in Japan.

Takeda M, Ishida T, Ohnuki K, Suzuki A, Sakayori M, Ishioka C, Nomizu T, Noguchi S, Matsubara Y, Ohuchi N.

Breast Cancer. 2004;11(1):30-2.

PMID:
14718789
17.

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.

Wolff TA, Wilson JE.

Am Fam Physician. 2006 Nov 15;74(10):1759-60. Review. No abstract available.

18.

BRCA1, BRCA2 and breast cancer: a concise clinical review.

Carter RF.

Clin Invest Med. 2001 Jun;24(3):147-57. Review.

PMID:
11437066
19.

Considerations in genetic counseling for inherited breast cancer predisposition.

Robson ME, Offit K.

Semin Radiat Oncol. 2002 Oct;12(4):362-70.

PMID:
12382194
20.

Predisposition testing for breast and ovarian cancer susceptibility.

Calzone KA.

Semin Oncol Nurs. 1997 May;13(2):82-90. Review.

PMID:
9114475

Supplemental Content

Support Center